Neuroimaging of Dystonia

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to investigate primary cervical dystonia as compared to healthy control subjects and DYT 1 dystonia as compared to healthy control subjects by examining cognitive measures, physical measures, and structural and functional magnetic resonance imaging (MRI).

The secondary aim of this study is to investigate a specific drug therapy for primary cervical dystonia to develop a functional MRI (fMRI) research paradigm. The drug, trihexyphenidyl, is FDA approved to treat Parkinson's Disease and is commonly prescribed by physicians as a treatment for symptoms of primary cervical dystonia.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Florida
• Collaborator: Bachmann Strauss Dystonia & Parkinson Foundation, Inc.
• Treatments: Polystyrene sulfonic acid; Trihexyphenidyl

Criteria

Inclusion Criteria:

• Diagnosis of primary cervical dystonia and between the ages of 18-70, OR

• Diagnosis of DYT 1 dystonia and between the ages of 7-50, OR

• Healthy control and between the ages of 7-70

Exclusion Criteria:

• Neurological impairment from: seizure disorders, stroke, hypertension, heart disease, diabetes, traumatic brain injury (TBI), drug abuse, nerve disorders, dementia, Parkinson's Disease, dementia

• Not a candidate for magnetic resonance imaging (MRI)

• Deep brain stimulation (DBS) surgery

• Any implanted electrical device

• Pregnant or planning pregnancy

• Breastfeeding

• Claustrophobia